Alcohol Abuse Clinical Trial
Official title:
SBIR-PhaseII, "Adaptive Goal-Directed Adherence Tracking and Enhancement"
Talaria, Inc., has designed an adherence tracking and enhancement system, called AGATE, which uses the text messaging and internet capabilities of modern cellular phones to address the problem of medication adherence in clinical care and clinical trial contexts. This trial will evaluate whether AGATE improves medication adherence in the context of a pharmacotherapy trial of naltrexone to treat problem drinking. All participants will be treatment-seeking problem drinkers who will receive naltrexone and medication monitoring over 8 weeks.
The purpose of the naltrexone trial is to evaluate whether AGATE effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking. Participants will be heavy/problem drinkers, recruited from the greater Albuquerque area, who are interested in either reducing or stopping their drinking and deemed to be candidates for naltrexone pharmacotherapy by the study psychiatrist, Dr. Arenella. All participants will be prescribed naltrexone, 50 mg, once daily, for eight weeks, and receive smartphones. Participants will be randomly assigned to receive either AGATE or SASED, a web-based alcohol and side-effects diary via smartphone. The primary outcome will be percent of scheduled doses that were taken during the eight week trial, as measured by the Medication Event Monitoring System (MEMS, Aardex Group, Union City, CA), pill counts, and using the timeline follow-back (TLFB) method. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03165942 -
Neuroendocrine Response to Oral Alcohol Administration
|
Phase 1 | |
| Recruiting |
NCT05343039 -
Technology Enhanced Adolescent Mental Health (TEAM)
|
N/A | |
| Active, not recruiting |
NCT04070521 -
EEG Monitoring in the Emergency Department
|
||
| Completed |
NCT03169244 -
Buproprion for Binge Drinking
|
Phase 2 | |
| Recruiting |
NCT05246202 -
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
|
N/A | |
| Completed |
NCT05036499 -
PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain
|
N/A | |
| Recruiting |
NCT04368416 -
Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
|
||
| Not yet recruiting |
NCT04557631 -
Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
|
||
| Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
| Completed |
NCT02681406 -
Smartphone Based Continuing Care for Alcohol
|
N/A | |
| Completed |
NCT02448134 -
A Community-Based Strategy for Preventing Underage Drinking
|
N/A | |
| Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
| Withdrawn |
NCT01796158 -
Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use
|
N/A | |
| Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
| Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
| Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
| Withdrawn |
NCT01511679 -
Brain-imaging and Adolescent Neuroscience Consortium
|
N/A | |
| Withdrawn |
NCT01275391 -
cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
| Completed |
NCT00907309 -
Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use
|
Phase 1/Phase 2 |